INFANRIX

국가: 이스라엘

언어: 영어

출처: Ministry of Health

유효 성분:

DIPHTHERIA TOXOID; FILAMENTOUS HAEMAGGLUTININ (FHA); PERTACTIN; PERTUSSIS TOXOID (PT); TETANUS TOXOID

제공처:

GLAXO SMITH KLINE (ISRAEL) LTD

ATC 코드:

J07CA

약제 형태:

SUSPENSION FOR INJECTION

구성:

DIPHTHERIA TOXOID NLT 30 IU; TETANUS TOXOID NLT 40 IU; PERTACTIN 8 MCG / 0.5 ML; FILAMENTOUS HAEMAGGLUTININ (FHA) 25 MCG / 0.5 ML; PERTUSSIS TOXOID (PT) 25 MCG / 0.5 ML

관리 경로:

I.M

처방전 유형:

Required

Manufactured by:

GLAXO SMITH KLINE BIOLOGICALS S.A

치료 그룹:

BACTERIAL AND VIRAL VACCINES, COMBINED

치료 징후:

Infanrix is indicated as a booster dose for children 15 months to 7 years of age who have previously been immunised with three or four doses of either DTPa vaccine or diphtheria, tetanus and whole-cell pertussis (DTPw) vaccine. Active primary immunisation against diphteria, tetanus and pertussis from the age 2 months onward.

승인 날짜:

2012-01-31

환자 정보 전단

העדוה
העדוה
לע
לע
הרמחה
הרמחה
עדימ (
עדימ (
ןולעב )תוחיטב
ןולעב )תוחיטב
אפורל
אפורל
ךיראת :
27.11.2012
םש
רישכת
תילגנאב :
INFANRIX
רפסמ
םושיר :
104-10-28630
םש
לעב
םושירה
GLAXOSMITHKLINE (ISRAEL) LTD :
םיטרפ
לע
םי/יונישה
םי/שקובמה
קרפ
ןולעב
טסקט
יחכונ
טסקט
שדח
WARNINGS AND
PRECAUTIONS
The potential risk of apnoea and the need for
respiratory monitoring for 48-72h should be
considered when administering the primary
immunization series to very premature
infants (born ≤ 28 weeks of gestation) and
particularly for those with a previous history
of respiratory immaturity. As the benefit of
vaccination is high in this group of infants,
vaccination should not be withheld or
delayed.
ADVERSE REACTIONS
Respiratory, thoracic and mediastinal
disorders:
Apnoea _[see section “Warnings and _
_Precautions” for apnoea in very premature _
_infants (≤ 28 weeks of gestation)_

제품 특성 요약

250
250
_The format of this leaflet was determined by the Ministry of Health
and its content _
_was checked and approved in April 2013_
INFANRIX
™
Diphtheria - Tetanus - acellular Pertussis Vaccine (DTPa)
SCOPE
TRADE NAME
Infanrix™
FORMULATION AND STRENGTH
Suspension for injection.
Infanrix contains diphtheria toxoid, tetanus toxoid and three purified
pertussis
antigens
[pertussis
toxoid
(PT),
filamentous
haemagglutinin
(FHA)
and
69
kiloDalton outer membrane protein (pertactin)] adsorbed onto aluminium
salts.
The diphtheria and tetanus toxins obtained from cultures of _
Corynebacterium _
_diphtheriae_ and _ Clostridium tetani_ are detoxified and purified.
The acellular
pertussis vaccine components (PT, FHA and pertactin) are prepared by
growing
phase I _ Bordetella pertussis_ from which the PT and FHA and
pertactin are
extracted, purified, and treated with formaldehyde; PT is irreversibly
detoxified.
The diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine
components
are adsorbed on aluminium salts. The final vaccine is formulated in
saline.
Infanrix meets the World Health Organisation requirements for
manufacture of
biological substances and for diphtheria and tetanus vaccines. No
substances of
human origin are used in its manufacture.
A 0.5 ml dose of the vaccine contains not less than 30 International
Units (IU) of
diphtheria toxoid, 40 IU of tetanus toxoid, 25 mcg of PT, 25 mcg of
FHA and 8
mcg of pertactin.
EXCIPIENTS
Aluminium hydroxide, sodium chloride, water for injections.
RESIDUES
Formaldehyde
Polysorbate 80
CLINICAL INFORMATION
INDICATIONS
Infanrix
is indicated for active primary immunisation against diphtheria,
tetanus
and pertussis from the age of 2 months onwards.
Infanrix
is indicated as a booster dose for children 15 months to 7 years of
age
who have previously been immunised with three or four doses of either
DTPa
vaccine or diphtheria, tetanus and whole-cell pertussis (DTPw)
vaccine.
DOSAGE AND ADMINISTRATION
POSOLOGY
The recommended dose (0.5 ml) of the vaccine must be administ